XML 33 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Information
 9 Months Ended 12 Months Ended
Jan. 31, 2016
Apr. 30, 2015
Segment Reporting [Abstract]    
Segment Reporting Disclosure [Text Block]

Note 8. Segment Information

The Company operates in two reportable segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2015, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
 
 
Three Months Ended January 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
416
 
 
$
2,136
 
 
$
—
 
 
$
2,552
 
Direct cost of services
 
 
(479
) 
 
 
(1,624
) 
 
 
—
 
 
 
(2,103
) 
Sales and marketing costs
 
 
(183
) 
 
 
(569
) 
 
 
—
 
 
 
(752
) 
Other operating expenses
 
 
—
 
 
 
(950
) 
 
 
(553
) 
 
 
(1,503
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(567
) 
 
 
(567
) 
Segment profit (loss)
 
$
(246
) 
 
$
(1,007
) 
 
$
(1,120
) 
 
$
(2,373
) 
 
 
 
Three Months Ended January 31, 2015
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
453
 
 
$
1,376
 
 
$
—
 
 
$
1,829
 
Direct cost of services
 
 
(672
) 
 
 
(1,300
) 
 
 
—
 
 
 
(1,972
) 
Sales and marketing costs
 
 
(366
) 
 
 
(613
) 
 
 
—
 
 
 
(979
) 
Other operating expenses
 
 
—
 
 
 
(1,028
) 
 
 
(612
) 
 
 
(1,640
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(657
) 
 
 
(657
) 
Segment profit (loss)
 
$
(585
) 
 
$
(1,565
) 
 
$
(1,269
) 
 
$
(3,419
) 
 
 
 
Nine Months Ended January 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,387
 
 
$
6,958
 
 
$
—
 
 
$
8,345
 
Direct cost of services
 
 
(1,634
) 
 
 
(4,654
) 
 
 
—
 
 
 
(6,288
) 
Sales and marketing costs
 
 
(716
) 
 
 
(1,800
) 
 
 
—
 
 
 
(2,516
) 
Other operating expenses
 
 
—
 
 
 
(2,755
) 
 
 
(2,463
) 
 
 
(5,218
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(2,090
) 
 
 
(2,090
) 
Segment profit (loss)
 
$
(963
) 
 
$
(2,251
) 
 
$
(4,553
) 
 
$
(7,767
) 
 
 
Nine Months Ended January 31, 2015
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,245
 
 
$
4,377
 
 
$
—
 
 
$
5,622
 
Direct cost of services
 
 
(2,171
) 
 
 
(3,205
) 
 
 
—
 
 
 
(5,376
) 
Sales and marketing costs
 
 
(1,243
) 
 
 
(1,650
) 
 
 
—
 
 
 
(2,893
) 
Other operating expenses
 
 
—
 
 
 
(3,490
) 
 
 
(2,413
) 
 
 
(5,903
) 
Stock-based compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(2,284
) 
 
 
(2,284
) 
Segment profit (loss)
 
$
(2,169
) 
 
$
(3,968
) 
 
$
(4,697
) 
 
$
(10,834
) 
 
(1)
 Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Note 10. Business Segment Information

The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
 
 
Year Ended April 30, 2015
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,663
 
 
$
7,200
 
 
$
—
 
 
$
8,863
 
Direct cost of services
 
 
(2,711
) 
 
 
(4,877
) 
 
 
—
 
 
 
(7,588
) 
Sales and marketing costs
 
 
(1,514
) 
 
 
(2,208
) 
 
 
—
 
 
 
(3,722
) 
Other operating expenses
 
 
—
 
 
 
(4,493
) 
 
 
(3,136
) 
 
 
(7,729
) 
Stock compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(3,162
) 
 
 
(3,162
) 
Segment profit (loss)
 
$
(2,562
) 
 
$
(4,378
) 
 
$
(6,298
) 
 
$
(13,238
) 
 
 
 
Year Ended April 30, 2014
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
2,264
 
 
$
9,286
 
 
$
—
 
 
$
11,550
 
Direct cost of services
 
 
(2,667
) 
 
 
(3,496
) 
 
 
—
 
 
 
(6,163
) 
Sales and marketing costs
 
 
(1,723
) 
 
 
(1,080
) 
 
 
—
 
 
 
(2,803
) 
Other operating expenses
 
 
—
 
 
 
(2,209
) 
 
 
(3,828
) 
 
 
(6,037
) 
Stock compensation expense(1)
 
 
—
 
 
 
—
 
 
 
(2,807
) 
 
 
(2,807
) 
Segment loss
 
$
(2,126
) 
 
$
2,501
 
 
$
(6,635
) 
 
$
(6,260
) 
 
(1)
Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.